Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. For example, we sympathize with anyone who was caught holding Vascular Biogenics Ltd. (NASDAQ:VBLT) ...

In the annals of botched IPOs, there's the BATS disaster, and there's Facebook's notorious debut, but the train wreck that is Vascular Biogenics' IPO stands alone. The company priced its IPO on Nasdaq ...

Investors might want to bet on Vascular Biogenics (VBLT), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

It was the IPO that wasn't: A biotech firm hit the market and traded for six days, only to announce Friday that it wasn't issuing shares after all, thanks to a key investor's failure to follow through ...

Vascular Biogenics Ltd (NASDAQ:VBLT) shares are falling Wednesday after the company announced that the data from its Phase 3 OVAL trial of ofra-vec in platinum-resistant ovarian cancer did not meet ...

Shares drop after management announces the pricing terms of a recently announced secondary offering. Vascular Biogenics announced that it is raising $18.75 million from the sale of 2.5 million shares ...

Today we look at a small oncology concern headquartered in Israel that will have a poster presentation at the upcoming ASCO conference in Chicago in early June. It is well-funded, has upcoming ...